--- title: "European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading" type: "News" locale: "en" url: "https://longbridge.com/en/news/273260837.md" description: "European equities traded in the US saw a rise in American depositary receipts, increasing 0.49% to 1,744.86 on the S&P Europe Select ADR Index. Notable gainers included BioNTech (+4.8%) and Equinor (+2.6%), while decliners included Novo Nordisk (-3.3%) and Ascendis Pharma (-2.2%). From the UK and Ireland, Silence Therapeutics led with a 7.9% increase, while Mereo BioPharma Group dropped 7.3%." datetime: "2026-01-21T16:16:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/273260837.md) - [en](https://longbridge.com/en/news/273260837.md) - [zh-HK](https://longbridge.com/zh-HK/news/273260837.md) --- # European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading 11:16 AM EST, 01/21/2026 (MT Newswires) -- European equities traded in the US as American depositary receipts were tracking higher late Wednesday morning, rising 0.49% to 1,744.86 on the S&P Europe Select ADR Index. From continental Europe, the gainers were led by biotech firm BioNTech (BNTX) and petroleum refiner Equinor ( EQNR ) , which advanced 4.8% and 2.6% respectively. They were followed by biopharmaceutical company Grifols ( GRFS ) and semiconductor company Sequans Communications ( SQNS ) , which rose 2.1% and 1.7% respectively. The decliners from continental Europe were led by pharmaceutical companies Novo Nordisk ( NVO ) and Ascendis Pharma ( ASND ) , which fell 3.3% and 2.2% respectively. They were followed by internet advertising firm Criteo ( CRTO ) and biotech firm Evaxion ( EVAX ) , which lost 1.9% and 1.7% respectively. From the UK and Ireland, the gainers were led by pharmaceutical company Silence Therapeutics ( SLN ) and educational publisher Pearson (PSO), which increased 7.9% and 2.8% respectively. They were followed by software firm Endava ( DAVA ) and biopharmaceutical company NuCana ( NCNA ) , which were up 2.7% and 2.2% respectively. The decliners from the UK and Ireland were led by biopharmaceutical companies Mereo BioPharma Group ( MREO ) and Amarin ( AMRN ) , which dropped 7.3% and 2.7% respectively. They were followed by biopharmaceutical company Biodexa Pharmaceuticals ( BDRX ) and pharmaceutical company AstraZeneca ( AZN ) , which were down 1.8% and 0.6% respectively. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited. ### Related Stocks - [IHI.US](https://longbridge.com/en/quote/IHI.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [SPEU.US](https://longbridge.com/en/quote/SPEU.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [SSEHF.US](https://longbridge.com/en/quote/SSEHF.US.md) - [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [XLV.US](https://longbridge.com/en/quote/XLV.US.md) - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) - [IHE.US](https://longbridge.com/en/quote/IHE.US.md) - [BNTX.US](https://longbridge.com/en/quote/BNTX.US.md) - [NVO.US](https://longbridge.com/en/quote/NVO.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [ASND.US](https://longbridge.com/en/quote/ASND.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [EQNR.US](https://longbridge.com/en/quote/EQNR.US.md) - [SLN.US](https://longbridge.com/en/quote/SLN.US.md) - [MREO.US](https://longbridge.com/en/quote/MREO.US.md) - [STOHF.US](https://longbridge.com/en/quote/STOHF.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [XHE.US](https://longbridge.com/en/quote/XHE.US.md) ## Related News & Research - [Canada and India now have generic Wegovy. Here's why the U.S. doesn't.](https://longbridge.com/en/news/287250894.md) - [Wegovy Liver Data Broadens Semaglutide Story For Novo Nordisk Investors](https://longbridge.com/en/news/286980981.md) - [BREAKINGVIEWS-Berlin’s 2022 Uniper bailout could turn profitable](https://longbridge.com/en/news/286898283.md) - [Duality Biotherapeutics Exercises U.S. Cost and Profit-Sharing Option for BioNTech ADC](https://longbridge.com/en/news/286169551.md) - [Jenscare’s LuX-Valve Plus Shows Strong One-Year Results in Large Annulus Tricuspid Patients](https://longbridge.com/en/news/287144318.md)